CN115867554B - Brm靶向化合物和相关使用方法 - Google Patents

Brm靶向化合物和相关使用方法

Info

Publication number
CN115867554B
CN115867554B CN202180049461.6A CN202180049461A CN115867554B CN 115867554 B CN115867554 B CN 115867554B CN 202180049461 A CN202180049461 A CN 202180049461A CN 115867554 B CN115867554 B CN 115867554B
Authority
CN
China
Prior art keywords
pyrazino
ethyl
hexahydro
hydroxyphenyl
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180049461.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115867554A (zh
Inventor
安德鲁·保罗·库姆斯
林虹
菲利普·皮蒂斯
陆亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pruder Therapeutics Ltd
Original Assignee
Pruder Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pruder Therapeutics Ltd filed Critical Pruder Therapeutics Ltd
Publication of CN115867554A publication Critical patent/CN115867554A/zh
Application granted granted Critical
Publication of CN115867554B publication Critical patent/CN115867554B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180049461.6A 2020-06-09 2021-06-09 Brm靶向化合物和相关使用方法 Active CN115867554B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036811P 2020-06-09 2020-06-09
US63/036,811 2020-06-09
PCT/US2021/036664 WO2021252666A1 (en) 2020-06-09 2021-06-09 Brm targeting compounds and associated methods of use

Publications (2)

Publication Number Publication Date
CN115867554A CN115867554A (zh) 2023-03-28
CN115867554B true CN115867554B (zh) 2025-09-02

Family

ID=76731093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049461.6A Active CN115867554B (zh) 2020-06-09 2021-06-09 Brm靶向化合物和相关使用方法

Country Status (17)

Country Link
US (2) US11702423B2 (enExample)
EP (2) EP4161935B1 (enExample)
JP (1) JP2023529908A (enExample)
KR (1) KR20230037549A (enExample)
CN (1) CN115867554B (enExample)
AU (1) AU2021289730A1 (enExample)
BR (1) BR112022025061A2 (enExample)
CA (1) CA3185888A1 (enExample)
DK (1) DK4161935T3 (enExample)
ES (1) ES3034380T3 (enExample)
FI (1) FI4161935T3 (enExample)
IL (1) IL298933B2 (enExample)
MX (1) MX2022015732A (enExample)
PL (1) PL4161935T3 (enExample)
PT (1) PT4161935T (enExample)
WO (1) WO2021252666A1 (enExample)
ZA (1) ZA202213711B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2023278402A1 (en) * 2021-06-28 2023-01-05 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
JP2024533990A (ja) * 2021-08-09 2024-09-18 ジェネンテック， インコーポレイテッド Ｂｒｍの調節に使用するためのフェノール誘導体
AU2023270000A1 (en) * 2022-05-10 2024-11-28 Foghorn Therapeutics Inc. Pyrazine derivatives and uses thereof
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体
WO2024064316A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064328A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
AU2023356925A1 (en) * 2022-10-03 2025-04-24 Prelude Therapeutics Incorporated Improved treatment of cancers using combinations of SMARCA2 degraders and KRAS targeting therapies
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
WO2025076351A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with gemcitabine
US20250114354A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with pd-1 inhibitors
US20260115189A1 (en) 2023-10-04 2026-04-30 Prelude Therapeutics Incorporated Combination Treatment Regimens - SMARCA2 Degrader With Taxane Anticancer Agent
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2026039756A1 (en) * 2024-08-16 2026-02-19 Prelude Therapeutics Incorporated Methods of treating cancer using a smarca2 degrader
WO2026090411A1 (en) * 2024-10-23 2026-04-30 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
CN119638700B (zh) * 2024-11-01 2025-11-14 中科中山药物创新研究院 一种nsd2降解剂及其应用
WO2026152359A1 (en) * 2025-01-17 2026-07-23 Prelude Therapeutics Incorporated Polymorphic compounds and uses thereof
WO2026156670A1 (en) 2025-01-24 2026-07-30 Prelude Therapeutics Incorporated Processes for making smarca2 degraders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138114A1 (en) * 2015-02-25 2016-09-01 Genentech, Inc. Therapeutic pyridazine compounds and uses thereof
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
US20220324880A1 (en) 2019-06-10 2022-10-13 Kymara Therapeutics, Inc. Smarca inhibitors and uses thereof
US20230087825A1 (en) 2019-06-10 2023-03-23 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021133917A1 (en) * 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) * 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138114A1 (en) * 2015-02-25 2016-09-01 Genentech, Inc. Therapeutic pyridazine compounds and uses thereof
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Also Published As

Publication number Publication date
EP4161935A1 (en) 2023-04-12
IL298933B1 (en) 2026-04-01
IL298933B2 (en) 2026-08-01
US20240018158A1 (en) 2024-01-18
BR112022025061A2 (pt) 2023-01-31
EP4570319A2 (en) 2025-06-18
ZA202213711B (en) 2026-04-29
EP4161935B1 (en) 2025-05-21
AU2021289730A1 (en) 2023-01-19
DK4161935T3 (da) 2025-08-18
EP4570319A3 (en) 2025-08-20
MX2022015732A (es) 2023-02-13
JP2023529908A (ja) 2023-07-12
CA3185888A1 (en) 2021-12-16
WO2021252666A1 (en) 2021-12-16
US11702423B2 (en) 2023-07-18
AU2021289730A8 (en) 2023-02-02
US20220033409A1 (en) 2022-02-03
KR20230037549A (ko) 2023-03-16
IL298933A (en) 2023-02-01
PL4161935T3 (pl) 2025-09-08
FI4161935T3 (fi) 2025-08-19
ES3034380T3 (en) 2025-08-18
CN115867554A (zh) 2023-03-28
PT4161935T (pt) 2025-08-14

Similar Documents

Publication Publication Date Title
US11702423B2 (en) BRM targeting compounds and associated methods of use
ES2965468T3 (es) Compuestos heterocíclicos para uso en el tratamiento del cáncer
AU2017207268A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
KR20190075931A (ko) 스피로 고리 화합물
BR112021008796A2 (pt) derivados de espiro-sulfonamida como inibidores de proteína de leucemia-1 de células mieloides (mcl-1)
CN119487036A (zh) 作为smarca4蛋白降解剂用于治疗癌症的6,6a,7,8,9,10-六氢-5h-吡嗪并[1',2':4,5]吡嗪并[2,3-c]哒嗪衍生物
US20240261418A1 (en) Sos1 degrading agent and preparation method therefor and application thereof
EP4519259A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CN120418251A (zh) Brm靶向化合物和相关使用方法
CN119836416A (zh) 具有泛素连接酶结合部分的靶向kat6的化合物
WO2023215449A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
US20240336612A1 (en) BRM Targeting Compounds And Associated Methods Of Use
HK40128204A (en) Brm targeting compounds and associated methods of use
EA048707B1 (ru) Brm направленные соединения и связанные способы применения
EA050840B1 (ru) Brm направленные соединения и связанные способы применения
WO2025117881A1 (en) Compounds and methods for inhibiting autophagy
US20250161289A1 (en) KAT6 Targeting Compounds
HK40078801B (en) Heterocyclic compounds for use in the treatment of cancer
HK40078801A (en) Heterocyclic compounds for use in the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant